168 related articles for article (PubMed ID: 35389210)
1. Toward the Design of Ligands Selective for the C-Terminal Domain of TEADs.
Liberelle M; Toulotte F; Renault N; Gelin M; Allemand F; Melnyk P; Guichou JF; Cotelle P
J Med Chem; 2022 Apr; 65(8):5926-5940. PubMed ID: 35389210
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors.
Lu W; Fan M; Ji W; Tse J; You I; Ficarro SB; Tavares I; Che J; Kim AY; Zhu X; Boghossian A; Rees MG; Ronan MM; Roth JA; Hinshaw SM; Nabet B; Corsello SM; Kwiatkowski N; Marto JA; Zhang T; Gray NS
J Med Chem; 2023 Apr; 66(7):4617-4632. PubMed ID: 36946421
[TBL] [Abstract][Full Text] [Related]
3. Discovering inhibitors of TEAD palmitate binding pocket through virtual screening and molecular dynamics simulation.
Li Y; Li Y; Ning C; Yue J; Zhang C; He X; Wang Y; Liu Z
Comput Biol Chem; 2022 Jun; 98():107648. PubMed ID: 35288361
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
[TBL] [Abstract][Full Text] [Related]
5. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.
Hori N; Okada K; Takakura Y; Takano H; Yamaguchi N; Yamaguchi N
J Biol Chem; 2020 Jun; 295(26):8798-8807. PubMed ID: 32385107
[TBL] [Abstract][Full Text] [Related]
6. Identification of Quinolinols as Activators of TEAD-Dependent Transcription.
Pobbati AV; Mejuch T; Chakraborty S; Karatas H; Bharath SR; Guéret SM; Goy PA; Hahne G; Pahl A; Sievers S; Guccione E; Song H; Waldmann H; Hong W
ACS Chem Biol; 2019 Dec; 14(12):2909-2921. PubMed ID: 31742995
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of TEAD transcription factors in cancer.
Pobbati AV; Kumar R; Rubin BP; Hong W
Trends Biochem Sci; 2023 May; 48(5):450-462. PubMed ID: 36709077
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the Hippo Pathway Transcription Factor TEAD.
Lin KC; Park HW; Guan KL
Trends Biochem Sci; 2017 Nov; 42(11):862-872. PubMed ID: 28964625
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3.
Lu T; Li Y; Lu W; Spitters T; Fang X; Wang J; Cai S; Gao J; Zhou Y; Duan Z; Xiong H; Liu L; Li Q; Jiang H; Chen K; Zhou H; Lin H; Feng H; Zhou B; Antos CL; Luo C
Acta Pharm Sin B; 2021 Oct; 11(10):3206-3219. PubMed ID: 34729310
[TBL] [Abstract][Full Text] [Related]
10. Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling.
Noland CL; Gierke S; Schnier PD; Murray J; Sandoval WN; Sagolla M; Dey A; Hannoush RN; Fairbrother WJ; Cunningham CN
Structure; 2016 Jan; 24(1):179-186. PubMed ID: 26724994
[TBL] [Abstract][Full Text] [Related]
11. Protein-Protein Interaction Disruptors of the YAP/TAZ-TEAD Transcriptional Complex.
Pobbati AV; Rubin BP
Molecules; 2020 Dec; 25(24):. PubMed ID: 33352993
[TBL] [Abstract][Full Text] [Related]
12. TEAD1 regulates cell proliferation through a pocket-independent transcription repression mechanism.
Li F; Negi V; Yang P; Lee J; Ma K; Moulik M; Yechoor VK
Nucleic Acids Res; 2022 Dec; 50(22):12723-12738. PubMed ID: 36484096
[TBL] [Abstract][Full Text] [Related]
13. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
14. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling.
Ota M; Sasaki H
Development; 2008 Dec; 135(24):4059-69. PubMed ID: 19004856
[TBL] [Abstract][Full Text] [Related]
15. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy.
Pobbati AV; Hong W
Theranostics; 2020; 10(8):3622-3635. PubMed ID: 32206112
[TBL] [Abstract][Full Text] [Related]
16. Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy.
Bokhovchuk F; Mesrouze Y; Izaac A; Meyerhofer M; Zimmermann C; Fontana P; Schmelzle T; Erdmann D; Furet P; Kallen J; Chène P
FEBS J; 2019 Jun; 286(12):2381-2398. PubMed ID: 30903741
[TBL] [Abstract][Full Text] [Related]
17. Establishment of transgenic lines to monitor and manipulate Yap/Taz-Tead activity in zebrafish reveals both evolutionarily conserved and divergent functions of the Hippo pathway.
Miesfeld JB; Link BA
Mech Dev; 2014 Aug; 133():177-88. PubMed ID: 24560909
[TBL] [Abstract][Full Text] [Related]
18. Targeting YAP/TAZ-TEAD protein-protein interactions using fragment-based and computational modeling approaches.
Kaan HYK; Sim AYL; Tan SKJ; Verma C; Song H
PLoS One; 2017; 12(6):e0178381. PubMed ID: 28570566
[TBL] [Abstract][Full Text] [Related]
19. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present).
Zagiel B; Melnyk P; Cotelle P
Expert Opin Ther Pat; 2022 Aug; 32(8):899-912. PubMed ID: 35768160
[TBL] [Abstract][Full Text] [Related]
20. Regulation of TEAD Transcription Factors in Cancer Biology.
Huh HD; Kim DH; Jeong HS; Park HW
Cells; 2019 Jun; 8(6):. PubMed ID: 31212916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
